Business Context and Reporting Period
This Form 8-K Current Report was filed by NextCure, Inc. on October 2, 2019. The report discloses a corporate governance change involving the promotion of an executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Timothy Mayer, Ph.D., to the newly created position of Chief Operating Officer (COO), effective October 2, 2019. Dr. Mayer previously served as Senior Vice President, Corporate Development, and Vice President, Business Development at the company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk disclosures beyond the standard regulatory context. The promotion was announced via a press release attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for additional context on the COO appointment.
- Review Dr. Mayer's background and prior roles at MacroGenics, Inc. and Banner & Witcoff, Ltd. as detailed in the filing.
- Confirm that no other material events were reported in this specific filing.